Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06369181Recruiting
Study on cell changes in lung cancer with RB1/TP53 gene changes
This trial looks at what happens when certain types of non-small cell lung cancer—those with changes in the RB1 and TP53 genes—start to change into another type of lung cancer after treatment. It may help find better ways to treat this specific kind of cancer in the future.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06389422RecruitingPhase 2
Radiation plus Keytruda for liver cancer with vein clots
This trial tests a combination of moderate-dose radiation therapy and the immunotherapy drug pembrolizumab (Keytruda) for liver cancer that has spread into the main veins of the liver. It aims to see if this combination can shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–90 - NCT06391190RecruitingPhase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
ShanghaiAges 18–75 - NCT05868174RecruitingPhase 1
Testing a targeted radiation drug plus a DNA repair blocker
This early-phase trial tests whether combining a targeted radiation medicine (177Lu-TLX250) with a DNA repair–blocking drug (peposertib) can shrink advanced solid tumors. It is designed for tumors that strongly show a marker called CAIX, which helps the radiation home in and may make treatment more effective.
North Ryde, New South WalesAges 18 years+ - NCT06282497Recruiting
New radiation technique to reduce dry mouth in nasopharyngeal cancer
This trial compares a new radiation technique designed to reduce dry mouth (xerostomia) with standard radiation for people with nasopharyngeal cancer. It aims to see if the new approach can protect saliva glands while still treating the cancer effectively.
Zhongshan, GuangdongAges 18–70 - NCT06190782RecruitingPhase 3
Local therapy for limited metastatic esophageal cancer
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
ShanghaiAges 18 years+ - NCT06401304Recruiting
Value-based breast surgery outcomes study
This study looks at how well breast-conserving surgery (lumpectomy) works for women with breast cancer or other breast conditions. It will track how you feel, how you look, and your overall satisfaction to help improve future care.
SydneyAges 18 years+ - NCT06311929RecruitingPhase 4
Personalized treatment after liver cancer surgery
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
Wuhan, HubeiAges 18–75 - NCT06397222RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT04680377Recruiting
Using gut microbes to predict durvalumab side effects in lung cancer
This study looks at the microbiome (the tiny organisms in your gut) to try to predict who will get side effects from durvalumab after chemoradiation. If you join, your care team will use your microbiome results to help understand toxicity risk and improve future treatment planning.
Kansas City, KansasAges 18 years+ - NCT05842629Recruiting
Better ways to diagnose ovarian cancer
This study focuses on improving diagnosis of ovarian cancer. If you have an abnormal mass seen on ultrasound near the ovaries, the researchers may evaluate how best to identify whether it could be ovarian cancer.
AarhusAges Any age - NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT06410651RecruitingPhase 2
Nimotuzumab with chemoradiation for advanced esophageal cancer
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
BeijingAges 18–80 - NCT06413992RecruitingPhase 2
Camrelizumab plus fluzoparib for TP53-mutated endometrial cancer
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06417736Recruiting
Study on Endometrial Cancer and Precancer in Young Women
This study tests whether certain treatments can help women aged 18-45 with early-stage endometrial cancer or precancerous changes keep their ability to have children. It uses imaging scans to make sure the cancer hasn't spread.
Hangzhou, ZhejiangAges 18–45 - NCT06420258RecruitingPhase 4
Deeper intubation for cervical esophageal cancer removal
This study tests if inserting the endoscope deeper helps remove early-stage cervical esophageal cancer or precancerous cells more effectively. It may offer a safer, less invasive option for you.
Fuzhou, FujianAges 18–80 - NCT06418165Recruiting
Cooled oxygenated machine perfusion for liver transplant
This study tests a new way to preserve donated livers using a machine that keeps the organ cool and oxygenated before transplant. It may help improve how well the liver works after the surgery.
ViennaAges 18 years+ - NCT06353685RecruitingPhase 2
Less radiation after surgery for oral cancer with good response
This trial is testing whether giving less radiation after surgery is safe and effective for people with oral cancer whose surgery results were very good (no cancer cells or very few left). It aims to reduce side effects while still preventing cancer from coming back.
GuangzhouAges 18–80 - NCT06408584Recruiting
Short radiation plus two drugs for returning esophageal cancer
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
HefeiAges 18 years+ - NCT04694924Recruiting
Prostate cancer patient registry to track experiences
This study builds a database of people with localized or locally advanced prostate cancer to better understand patient-reported outcomes (your experiences and quality-of-life). It may help improve future care by collecting consistent feedback from patients.
Dendermonde, Oost-VlaanderenAges 18 years+ - NCT06204835RecruitingPhase 1
ITGA6-targeted dye for liver cancer surgery guidance
This trial uses a special dye that lights up during surgery to help doctors see and remove liver cancer cells that have a specific protein (ITGA6). It aims to make surgery more precise and effective.
Guangzhou, GuangdongAges 18–80 - NCT07843940RecruitingPhase 1/Phase 2
Two study drugs for extensive-stage small cell lung cancer
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
Miami, FloridaAges 18 years+ - NCT07848854RecruitingPhase 2
New imaging test to spot bladder cancer during surgery
This trial tests a special dye that binds to bladder cancer cells and makes them glow during surgery. It may help doctors find and remove the cancer more completely.
Kunming, YunnanAges 18–80
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,124 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.